How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    a. Has all of the relevant evidence been taken into account?

  • Question on Consultation

    b. Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    c. Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    d. Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about cabozantinib

Anticipated marketing authorisation indication

2.1

Cabozantinib (Cabometyx, Ipsen) is indicated 'for the treatment of adult patients with unresectable or metastatic well-differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumours who have progressed following at least one prior systemic therapy other than somatostatin analogues'.

Dosage in the marketing authorisation

2.2

The dosage schedule is available in the summary of product characteristics for cabozantinib.

Price

2.3

The list price of cabozantinib is £5,143 for a 30-day pack of 60-mg capsules

2.4

The company has a commercial arrangement. This makes cabozantinib available to the NHS with a discount and it would have also applied to this indication if cabozantinib had been recommended. The size of the discount is commercial in confidence.

Carbon Reduction Plan

2.5

Information on the Carbon Reduction Plan for UK carbon emissions for Ipsen will be included here when guidance is published.